MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, PFE had $91M increase in cash & cash equivalents over the period. $9,075M in free cash flow.

Cash Flow Overview

Change in Cash
$91M
Free Cash flow
$9,075M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
    • Proceeds from redemptions/sales ...
    • Proceeds from issuance of long-t...
    • Net income from continuing opera...
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Cash dividends paid
    • Acquisitions of businesses, net ...
    • Others

Cash Flow
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Net income from continuing operations before allocation to noncontrolling interests
7,787 8,051 2,172 31,401
Depreciation and amortization
6,592 7,013 6,290 5,064
Asset write-offs and impairments
5,270 4,242 3,408 550
Deferred taxes
-2,133 -2,102 -3,442 -3,764
Share-based compensation expense
799 877 525 872
Benefit plan contributions in excess of expense/income
786 12 787 1,158
Inventory write-offs and related charges associated with covid-19 products
0 0 6,199 -
Other adjustments, net
470 2,260 3,492 -758
Trade accounts receivable
263 109 -347 -261
Inventories
-561 854 1,169 -592
Other assets
-1,289 -3,380 663 4,506
Trade accounts payable
-469 -1,023 -300 1,191
Other liabilities
-3,667 -3,115 595 -1,449
Other tax accounts, net
-2,805 -1,345 -982 -545
Net cash provided by/(used in) operating activities from continuing operations
--8,700 29,267
Net cash provided by/(used in) operating activities from discontinued operations
--0 0
Net cash provided by/(used in) operating activities
11,704 12,744 8,700 29,267
Purchases of property, plant and equipment
2,629 2,909 3,907 3,236
Purchases of short-term investments
14,356 10,133 30,974 36,384
Proceeds from redemptions/sales of short-term investments
17,959 4,128 39,264 44,821
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less
2,675 -3,136 -5,174 483
Purchases of long-term investments
294 180 204 1,913
Proceeds from redemptions/sales of long-term investments
1,095 1,570 1,979 641
Proceeds from partial sales of investment in haleon
6,311 7,040 --
Acquisitions of businesses, net of cash acquired
6,927 0 43,430 22,997
Dividend received from the consumer healthcare jv
-0 0 3,960
Other investing activities, net
-165 -179 192
Net cash provided by/(used in) investing activities from continuing operations
---32,278 -15,783
Net cash provided by/(used in) investing activities from discontinued operations
--0 0
Net cash provided by/(used in) investing activities
-1,351 2,652 -32,278 -15,783
Proceeds from short-term borrowings
0 8,907 4,525 3,891
Payments on short-term borrowings
2,199 11,226 3 3,887
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
-796 -2,590 3,161 -222
Proceeds from issuance of long-term debt
9,678 0 30,831 0
Payments on long-term debt
6,757 2,250 2,569 3,298
Purchases of common stock
-0 0 2,000
Cash dividends paid
9,771 9,512 9,247 8,983
Other financing activities, net
-458 -469 -631 -335
Net cash provided by/(used in) financing activities from continuing operations
----14,834
Net cash provided by/(used in) financing activities from discontinued operations
---0
Net cash provided by/(used in) financing activities
-10,304 -17,140 26,066 -14,834
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
41 -66 -40 -165
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents
91 -1,810 2,448 -1,515
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period
1,107 2,917 468 1,983
Cash and cash equivalents and restricted cash and cash equivalents, at end of period
1,197 1,107 2,917 468
Unit: Million (M) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net income fromcontinuing operations...$7,787M (-3.28%↓ Y/Y)Depreciation andamortization$6,592M (-6.00%↓ Y/Y)Asset write-offs andimpairments$5,270M (24.23%↑ Y/Y)Other assets-$1,289M (61.86%↑ Y/Y)Share-based compensationexpense$799M (-8.89%↓ Y/Y)Inventories-$561M (-165.69%↓ Y/Y)Net cash providedby/(used in) operating...$11,704M (-8.16%↓ Y/Y)Effect ofexchange-rate changes on cash...$41M (162.12%↑ Y/Y)Canceled cashflow$10,593M Netincrease/(decrease) in cash and cash...$91M (105.03%↑ Y/Y)Canceled cashflow$11,655M Other liabilities-$3,667M (-17.72%↓ Y/Y)Other tax accounts,net-$2,805M (-108.55%↓ Y/Y)Deferred taxes-$2,133M (-1.47%↓ Y/Y)Benefit plancontributions in excess of...$786M (6450.00%↑ Y/Y)Other adjustments,net$470M (-79.20%↓ Y/Y)Trade accountspayable-$469M (54.15%↑ Y/Y)Trade accountsreceivable$263M (141.28%↑ Y/Y)Proceeds from issuance oflong-term debt$9,678M Proceeds fromredemptions/sales of short-term...$17,959M (335.05%↑ Y/Y)Proceeds from partialsales of investment in...$6,311M (-10.36%↓ Y/Y)Proceeds fromredemptions/sales of long-term...$1,095M (-30.25%↓ Y/Y)Other investingactivities, net-$165M Net cash providedby/(used in) financing...-$10,304M (39.88%↑ Y/Y)Net cash providedby/(used in) investing...-$1,351M (-150.94%↓ Y/Y)Canceled cashflow$9,678M Canceled cashflow$25,530M Cash dividends paid$9,771M (2.72%↑ Y/Y)Payments on long-termdebt$6,757M (200.31%↑ Y/Y)Purchases of short-terminvestments$14,356M (41.68%↑ Y/Y)Payments on short-termborrowings$2,199M (-80.41%↓ Y/Y)Net (paymentson)/proceeds from short-term...-$796M (69.27%↑ Y/Y)Other financingactivities, net-$458M (2.35%↑ Y/Y)Acquisitions of businesses,net of cash acquired$6,927M Net (purchasesof)/proceeds from...$2,675M (185.30%↑ Y/Y)Purchases of property,plant and equipment$2,629M (-9.63%↓ Y/Y)Purchases of long-terminvestments$294M (63.33%↑ Y/Y)

Pfizer_(2021)-svg

PFIZER INC (PFE)

Pfizer_(2021)-svg

PFIZER INC (PFE)